Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer- binding protein α

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 3866-3877

  Zhang, Yan ^a   Ma, Xiaojing ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 12; INTERLEUKIN 23; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SERINE; THREONINE; TRIPTOLIDE; DITERPENE; EPITOPE; EPOXIDE; IMMUNOSUPPRESSIVE AGENT; P40, IODINATED C TERMINAL PEPTIDE, HUMAN; P40, IODINATED C-TERMINAL PEPTIDE, HUMAN; PEPTIDE FRAGMENT; PHENANTHRENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENETIC TRANSCRIPTION; HERBAL MEDICINE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROPHAGE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TRANSCRIPTION INITIATION; ANIMAL; BIOSYNTHESIS; DNA MICROARRAY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DITERPENES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOXY COMPOUNDS; GENE EXPRESSION; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12; INTERLEUKIN-23; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; PHENANTHRENES; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 77951644674     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903417     Document Type: Article

References (74)

1. Kupchan, S. M., W. A. Court, R. G. Dailey, Jr., C. J. Gilmore, and R. F. Bryan. 1972. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J. Am. Chem. Soc. 94: 7194-7195.
2. Tao, X. L., Y. Sun, Y. Dong, Y. L. Xiao, D. W. Hu, Y. P. Shi, Q. L. Zhu, H. Dai, and N. Z. Zhang. 1989. A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin. Med. J. (Engl.) 102: 327-332.
3. Qin, W. Z., G. D. Zhu, S. M. Yang, K. Y. Han, and J. Wang. 1983. Clinical observations on Tripterygium wilfordii in treatment of 26 cases of discoid lupus erythematosus. J. Tradit. Chin. Med. 3: 131-132.
4. Jiang, X. 1994. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr. Nephrol. 8: 343-344.
5. Xu, W. Y., J. R. Zheng, and X. Y. Lu. 1985. Tripterygium in dermatologic therapy. Int. J. Dermatol. 24: 152-157.
6. Mao, H., X. R. Chen, Q. Yi, S. Y. Li, Z. L. Wang, and F. Y. Li. 2008. Mycophenolate mofetil and triptolide alleviating airway inflammation in asthmatic model mice partly by inhibiting bone marrow eosinophilopoiesis. Int. Immunopharmacol. 8: 1039-1048.
7. Chen, T., H. Xu, H. Q. Wang, Y. Zhao, C. F. Zhu, Y. H. Zhang, M. J. Ji, Y. B. Hua, and W. X. Wu. 2008. Prolongation of rat intestinal allograft survival by administration of triptolide-modified donor bone marrow-derived dendritic cells. Transplant. Proc. 40: 3711-3713.
8. Liu, Y., Y. Chen, F. Q. Liu, J. R. Lamb, and P. K. Tam. 2008. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl. Int. 21: 483-494.
9. Qiu, D., G. Zhao, Y. Aoki, L. Shi, A. Uyei, S. Nazarian, J. C. Ng, and P. N. Kao. 1999. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J. Biol. Chem. 274: 13443-13450.
10. Numerof, R. P., and K. Asadullah. 2006. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 20: 93-103.
11. Qiu, D, and P. N. Kao. 2003. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medical herb Tripterygium wilfordii Hook F. Drugs R D. 4: 1-18.
12. Liu, Q., T. Chen, H. Chen, M. Zhang, N. Li, Z. Lu, P. Ma, and X. Cao. 2004. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem. Biophys. Res. Commun. 319: 980-986.
13. Liu, H. K., S. Perrier, C. Lipina, D. Finlay, H. McLauchlan, C. J. Hastie, H. S. Hundal, and C. Sutherland. 2006. Functional characterisation of the regulation of CAAT enhancer binding protein alpha by GSK-3 phosphorylation of Threonines 222/226. BMC Mol. Biol. 7: 14.
14. Zhu, K. J., Q. Y. Shen, H. Cheng, X. H. Mao, L. M. Lao, and G. L. Hao. 2005. Triptolide affects the differentiation, maturation and function of human dendritic cells. Int. Immunopharmacol. 5: 1415-1426.
15. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
16. Tarrant, T. K., P. B. Silver, C. C. Chan, B. Wiggert, and R. R. Caspi. 1998. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J. Immunol. 161: 122-127. (Pubitemid 28285514)
17. Hue, S., P. Ahern, S. Buonocore, M. C. Kullberg, D. J. Cua, B. S. McKenzie, F. Powrie, and K. J. Maloy. 2006. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203: 2473-2483.
18. Meyts, I., P. W. Hellings, G. Hens, B. M. Vanaudenaerde, B. Verbinnen, H. Heremans, P.Matthys, D.M. Bullens, L. Overbergh, C.Mathieu, et al. 2006. IL-12 contributes to allergen-induced airway inflammation in experimental asthma. J. Immunol. 177: 6460-6470.
19. Chen, X., T. Murakami, J. J. Oppenheim, and O. M. Howard. 2005. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 106: 2409-2416. (Pubitemid 41510814)
20. Liu, J., Q. L. Wu, Y. H. Feng, Y. F. Wang, X. Y. Li, and J. P. Zuo. 2005. Triptolide suppresses CD80 and CD86 expressions and IL-12 production in THP-1 cells. Acta Pharmacol. Sin. 26: 223-227.
21. Screpanti, I., P. Musiani, D. Bellavia, M. Cappelletti, F. B. Aiello, M. Maroder, L. Frati, A. Modesti, A. Gulino, and V. Poli. 1996. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J. Exp. Med. 184: 1561-1566.
22. Ma, X., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183: 147-157.
23. Cao, S., J. Liu, M. Chesi, P. L. Bergsagel, I. C. Ho, R. P. Donnelly, and X. Ma. 2002. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J. Immunol. 169: 5715-5725.
24. Chung, E. Y., J. Liu, Y. Homma, Y. Zhang, A. Brendolan, M. Saggese, J. Han, R. Silverstein, L. Selleri, and X. Ma. 2007. Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27: 952-964.
25. Plevy, S. E., J. H. Gemberling, S.Hsu, A. J. Dorner, and S. T. Smale. 1997.Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17: 4572-4588.
26. Ramji, D. P., and P. Foka. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365: 561-575. (Pubitemid 34864439)
27. Tengku-Muhammad, T. S., T. R. Hughes, H. Ranki, A. Cryer, and D. P. Ramji. 2000. Differential regulation of macrophage CCAAT-enhancer binding protein isoforms by lipopolysaccharide and cytokines. Cytokine 12: 1430-1436.
28. Poli, V. 1998. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J. Biol. Chem. 273: 29279-29282.
29. Ramji, D. P., A. Vitelli, F. Tronche, R. Cortese, and G. Ciliberto. 1993. The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res. 21: 289-294.
30. Descombes, P., and U. Schibler. 1991. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67: 569-579. (Pubitemid 121001471)
31. Homan, E. R., R. P. Zendzian, L. D. Schott, H. B. Levy, and R. H. Adamson. 1972. Studies on poly I:C toxicity in experimental animals. Toxicol. Appl. Pharmacol. 23: 579-588.
32. Legraverend, C., P. Antonson, P. Flodby, and K. G. Xanthopoulos. 1993. High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucleic Acids Res. 21: 1735-1742. (Pubitemid 23178886)
33. Christy, R. J., K. H. Kaestner, D. E. Geiman, and M. D. Lane. 1991. CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA 88: 2593-2597.
34. Cha, H. C., N. R. Oak, S. Kang, T. A. Tran, S. Kobayashi, S. H. Chiang, D. G. Tenen, and O. A. MacDougald. 2008. Phosphorylation of CCAAT/enhancer- binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. J. Biol. Chem. 283: 18002-18011.
35. Datta, J., S. Majumder, H. Kutay, T. Motiwala, W. Frankel, R. Costa, H. C. Cha, O. A. MacDougald, S. T. Jacob, and K. Ghoshal. 2007. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 67: 2736-2746.
36. Ross, S. E., R. L. Erickson, N. Hemati, and O. A. MacDougald. 1999. Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol. Cell. Biol. 19: 8433-8441.
37. Pedersen, T. A., O. Bereshchenko, S. Garcia-Silva, O. Ermakova, E. Kurz, S. Mandrup, B. T. Porse, and C. Nerlov. 2007. Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene expression in vivo. EMBO J. 26: 1081-1093. (Pubitemid 46303586)
38. Ross, S. E., H. S. Radomska, B. Wu, P. Zhang, J. N. Winnay, L. Bajnok, W. S. Wright, F. Schaufele, D. G. Tenen, and O. A. MacDougald. 2004. Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol. Cell. Biol. 24: 675-686.
39. Radomska, H. S., D. S. Bassères, R. Zheng, P. Zhang, T. Dayaram, Y. Yamamoto, D. W. Sternberg, N. Lokker, N. A. Giese, S. K. Bohlander, et al. 2006. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J. Exp. Med. 203: 371-381.
40. Klein, P. S., and D. A. Melton. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93: 8455-8459.
41. Owens, D. M., and S. M. Keyse. 2007. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213. (Pubitemid 46763015)
42. Kuwano, Y., H. H. Kim, K. Abdelmohsen, R. Pullmann, Jr., J. L. Martindale, X. Yang, and M. Gorospe. 2008. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol. Cell. Biol. 28: 4562-4575.
43. Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, and Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416. (Pubitemid 36903490)
44. Maehama, T., and J. E. Dixon. 1999. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9: 125-128. (Pubitemid 29161437)
45. Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski, and T. W. Mak. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39. (Pubitemid 28458022)
46. Tsugawa, K., M. K. Jones, K. Sugimachi, I. J. Sarfeh, and A. S. Tarnawski. 2002. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front. Biosci. 7: e245-e251.
47. Okamura, H., K. Yoshida, E. Sasaki, L. Qiu, B. R. Amorim, H. Morimoto, and T. Haneji. 2007. Expression of PTEN and Akt phosphorylation in lipopolysaccharide-treated NIH3T3 cells. Cell Biol. Int. 31: 119-125.
48. Hu, H. M., M. Baer, S. C. Williams, P. F. Johnson, and R. C. Schwartz. 1998. Redundancy of C/EBP alpha, -beta, and -delta in supporting the lipopolysaccharide-induced transcription of IL-6 and monocyte chemoattractant protein-1. J. Immunol. 160: 2334-2342.
49. Kinoshita, S., S. Akira, and T. Kishimoto. 1992. A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc. Natl. Acad. Sci. USA 89: 1473-1476.
50. Cardinaux, J. R., I. Allaman, and P. J. Magistretti. 2000. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 29: 91-97.
51. Tanaka, T., S. Akira, K. Yoshida, M. Umemoto, Y. Yoneda, N. Shirafuji, H. Fujiwara, S. Suematsu, N. Yoshida, and T. Kishimoto. 1995. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80: 353-361.
52. Screpanti, I., L. Romani, P. Musiani, A. Modesti, E. Fattori, D. Lazzaro, C. Sellitto, S. Scarpa, D. Bellavia, G. Lattanzio, et al. 1995. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 14: 1932-1941.
53. Lekstrom-Himes, J., and K. G. Xanthopoulos. 1998. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J. Biol. Chem. 273: 28545-28548.
54. Hendricks-Taylor, L. R., and G. J. Darlington. 1995. Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Nucleic Acids Res. 23: 4726-4733.
55. Zhang, D. E., P. Zhang, N. D. Wang, C. J. Hetherington, G. J. Darlington, and D. G. Tenen. 1997. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA 94: 569-574.
56. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
57. Keyse, S. M. 2000. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12: 186-192.
58. Franklin, C. C., and A. S. Kraft. 1997. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J. Biol. Chem. 272: 16917-16923.
59. -/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 176: 5788-5796.
60. Lu, H. T., D. D. Yang, M. Wysk, E. Gatti, I. Mellman, R. J. Davis, and R. A. Flavell. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18: 1845-1857.
61. Woodgett, J. R. 2005. Recent advances in the protein kinase B signaling pathway. Curr. Opin. Cell Biol. 17: 150-157.
62. Hazeki, K., K. Nigorikawa, and O. Hazeki. 2007. Role of phosphoinositide 3-kinase in innate immunity. Biol. Pharm. Bull. 30: 1617-1623.
63. Deane, J. A., and D. A. Fruman. 2004. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22: 563-598.
64. Fukao, T., M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, and S. Koyasu. 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3: 875-881.
65. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784.
66. Tonks, N. K. 2005. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670.
67. Lambeth, J. D. 2004. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 4: 181-189.
68. Hannken, T., R. Schroeder, R. A. Stahl, and G. Wolf. 2001. Atrial natriuretic peptide attenuates ANG II-induced hypertrophy of renal tubular cells. Am. J. Physiol. Renal Physiol. 281: F81-F90.
69. Yoneda, K., K. Peck, M. M. Chang, K. Chmiel, Y. P. Sher, J. Chen, P. C. Yang, Y. Chen, and R. Wu. 2001. Development of high-density DNA microarray membrane for profiling smoke- and hydrogen peroxide-induced genes in a human bronchial epithelial cell line. Am. J. Respir. Crit. Care Med. 164: S85-S89.
70. Fürst, R., C. Brueckl, W. M. Kuebler, S. Zahler, F. Krötz, A. Görlach, A. M. Vollmar, and A. K. Kiemer. 2005. Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ. Res. 96: 43-53.
71. Flaherty, D. M., M. M. Monick, and S. L. Hinde. 2006. Human alveolarmacrophages are deficient in PTEN. The role of endogenous oxidants. J. Biol. Chem. 281: 5058-5064.
72. Silva, A., J. A. Yunes, B. A. Cardoso, L. R. Martins, P. Y. Jotta, M. Abecasis, A. E. Nowill, N. R. Leslie, A. A. Cardoso, and J. T. Barata. 2008. PTEN post-translational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 118: 3762-3774.
73. Kupchan, S. M., and R. M. Schubert. 1974. Selective alkylation: a biomimetic reaction of the antileukemic triptolides? Science 185: 791-793.
74. Winterbourn, C. C., and M. B. Hampton. 2008. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 45: 549-561.